Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Zoetis Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.85 (market cap $3.56B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 8.5× GraniteShares 2x Long NVDA Daily ETF's market cap, and Zoetis Inc pays a 2.9% dividend while GraniteShares 2x Long NVDA Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and Zoetis Inc for 70 Days on average.
| NVDL | ZTS | |
|---|---|---|
Market Cap | $3.56B | $30.20B |
Volume | 9,740,643 | 6,175,327 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $147.53 |
52-Week Low | $21.76 | $69.09 |
Typical Hold Time | 15 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $36.86, down 6.85% in the last session. Technical indicators show a bullish overall signal with moving averages supporting upward momentum while oscillators remain neutral. Recent news highlights Nvidia's strong Q2 2027 earnings beat and ongoing AI theme strength, though the leveraged ETF has underperformed NVDA's direct returns over the past year.
The outlook remains tied to Nvidia's AI leadership and market performance, with technical support at $36 and resistance at $39. Key risks include leverage decay and NVDA's high valuation, while institutional interest in AI and positive analyst coverage provide potential upside catalysts for the leveraged ETF structure.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
